SCHEMBL10139876

SCHEMBL10139876

CN(C)C(=O)c1ccc2nc(-c3c(O)c(-c4ccccc4)nn3C)[nH]c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.52
CHEK2 O96017 5/20 0.48
CDK1 P06493 1/20 0.46
CDK2 P24941 1/20 0.46
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
F9 P00740 3/20 0.45
F10 P00742 3/20 0.45
F11 P03951 2/20 0.45
F7 P08709 2/20 0.45
HDAC3 O15379 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
ATR Q13535 1/20 0.45
HDAC2 Q92769 1/20 0.43
PLAU P00749 2/20 0.43
PRSS1 P07477 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGDS O60760 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7976986 0.89 CHEK2 (0.53) HDAC6CHEK2F9F10F11
SCHEMBL7975138 0.88 F10 (0.50) HDAC6CHEK2F9F10F11
SCHEMBL7969435 0.88 CHEK2 (0.65) CHEK2F9F10F11F7
SCHEMBL10139875 0.87 HDAC6 (0.49) HDAC6CHEK2CDK1CDK2MKNK1
SCHEMBL7961686 0.86 CHEK2 (0.58) HDAC6CHEK2CDK2F9F10
SCHEMBL10139933 0.86 CHEK2 (0.67) CHEK2
SCHEMBL10139808 0.82 P2RY6 (0.53) F9F10F11F7
SCHEMBL7976170 0.82 ITK (0.48) CDK2F9F10F11F7
SCHEMBL7975521 0.82 F10 (0.63) CHEK2F9F10F11F7
SCHEMBL7970842 0.81 NPC1 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805939-B1 Heterocyclic compounds as factor IXA inhibitors. MERCK SHARP & DOHME (US) 2018-06-27 EP disclosed
EP-2805939-A1 Heterocyclic compounds as factor IXA inhibitors. Merck Sharp & Dohme Corp. (US) 2014-11-26 EP disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 HDAC6 265/4885CHEK2 4794/4885CDK1 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.